AstraZeneca (AZN) Share Price & Analysis 524Followers AZN Stock Chart & Stats Advanced Chart > 10,768.00p 232.00p(2.20%) At close:Dec 044:00 PM EST Created with Highcharts 11.3.09 Sep23 Sep7 Oct21 Oct4 Nov18 Nov2 Dec9,000p10,000p11,000p12,000p13,000p14,000p010M...
Earnings per share 4.15 USD AstraZeneca PLC Price Chart Created with Highstock 7.0.2PriceVolume AstraZeneca PLCAZNCFFinancial and Trading Overview Contents AstraZeneca PLC Price Chart AstraZeneca PLCAZNCFFinancial and Trading Overview Valuation Measures ...
azncf earnings per share more on earnings » earnings estimates earnings revisions valuation growth profitability momentum capital structure azncf dividend growth history more on dividend growth » azncf ownership azncf peers risk technicals azncf transcripts investor presentations azncf sec filings ...
Despite the hefty cost of this acquisition, which is roughly 84% greater than its 30-day volume weight average price of $11.37 per share, AstraZeneca implies that the acquisition is a significant step forward for the company’s oncology portfolio....
AstraZeneca has a Zacks Rank #2 (Buy) currently. The Zacks Consensus Estimate for AstraZeneca’s 2024 EPS has risen from $4.04 per share to $4.08 per share over the past 60 days. The stock has risen 15.0% so far this year.
Share EquityWhat's this? Price(GBX) 10,524.000.53%(56.00) AZNORD SHS $0.25 Track6 more instruments Open/Last close 10,520.00/10,524.00 High/Low 10,606.00/10,482.00 Bid/Offer 10,522.00/10,524.00 Special Condition:- Trading Status:Normal - Closed ...
The shares have slipped from a year's high of 308p and are now at 291.5p. Car dealer Lookers' share price has taken off over the past year, climbing from 138p to 288.5p. It still yields 3.4 per cent and trades on a price earnings ratio of 12.6. With changes to the rules ...
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have improved from $1.24 to 48 cents. Estimates for 2025 have improved from $1.71 to $1.51 during the same period. Year to date, shares of Fulcrum Therapeutics have rallied 35.9%. Earnings of Fulcrum Therapeutics ...
22.28%Per cent of shares held by top holders HolderShares% Held BlackRock Investment Management (UK) Ltd.as of 31 Dec 202368.51m4.42% Wellington Management Co. LLPas of 31 Dec 202365.12m4.20% The Vanguard Group, Inc.as of 01 Nov 202456.76m3.66% ...
The deal values Alexion at $175 per share, a 45% premium to the Boston biotech’s closing price on Friday. As part of the cost will be paid in AstraZeneca shares, Alexion investors will own about 15% of the combined enterprise when the deal closes, likely in the third quarter of 2021...